InvestSMART

Botanix Pharmaceuticals Ltd (ASX:BOT)

ALERT: Price-sensitive ASX Announcement for BOT
Current share price for BOT : $0.023 -0.013 (-36.11%)+
Announcement
Release
16 Apr 2026 8:51AM
Price at Release
$0.036
Full Release
download
Summary
Botanix Pharmaceuticals Ltd has announced a term sheet agreement with PPL Pharma Solutions Riverview LLC (Piramal) to act as a second commercial supplier of Sofpironium Bromide, which is the active pharmaceutical ingredient in their FDA-approved product, Sofdra. This agreement is expected to lower the cost of goods by 25% to 40% and enhance gross profits by establishing an alternative supply chain route for Sofdra, thereby reducing risk.
Key Points
  • Botanix reaches agreement with Piramal for API supply.
  • The agreement aims to de-risk supply chain and reduce costs.
  • Sofpironium Bromide is the API in Sofdra, approved by FDA.
  • Piramal will commence development services immediately.
  • Potential cost reduction of 25% to 40% from the agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.